Thursday, May 23, 2013 Last update: 12:05 PM
Company Tech News as it Breaks
Trade Events
Alkermes plc
News articles for Alkermes plc:
Thursday, May 23, 2013
- Alkermes plc Reports Financial Results for Fiscal Year 2013 and Provides Financial ExpectationsAlkermes plc (NASDAQ: ALKS) today reported financial results for its fourth quarter and fiscal year ended March 31, 2013. The company also announced ... read more
Wednesday, May 22, 2013
- Alkermes Announces Data on ALKS 5461 and ALKS 3831 to Be Presented at 53rd Annual NCDEU MeetingAlkermes plc (NASDAQ: ALKS) today announced that clinical data on ALKS 5461, a novel drug candidate for major depressive disorder (MDD) in patients ... read more
Thursday, May 16, 2013
- Alkermes to Host Conference Call to Discuss Financial Results for Fiscal Year 2013Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:00 a.m. EDT (1:00 p.m. BST) on Thursday, May 23, 2013, to discuss the company’s ... read more
Wednesday, April 17, 2013
- Alkermes Announces Positive Results from Phase 2 Clinical Study of ALKS 5461 for Major Depressive DisorderAlkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for ... read more
Tuesday, February 19, 2013
- Alkermes’ Corporate Presentation to be Webcast at Three Upcoming ConferencesAlkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Citi 2013 Global Healthcare Conference on ... read more
Tuesday, February 5, 2013
- Alkermes’ Corporate Presentation to be Webcast at Two Upcoming ConferencesAlkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the 15th Annual BIO CEO & Investor ... read more
Thursday, January 31, 2013
- Alkermes plc Reports Third Quarter Fiscal 2013 Financial ResultsAlkermes plc (NASDAQ: ALKS) today reported financial results for its third quarter of fiscal 2013, which ended Dec. 31, 2012, and improved ... read more
Thursday, January 24, 2013
- Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2013Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EST (1:30 p.m. GMT) on Thursday, Jan. 31, 2013, to discuss the company’s ... read more
Thursday, January 3, 2013
- Alkermes Announces Notice of Allowance of Key U.S. Patent for Aripiprazole Lauroxil, a New Schizophrenia Drug CandidateAlkermes plc (NASDAQ: ALKS) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. ... read moreAlkermes Expands CNS Pipeline and Announces Positive Results from Phase 1 Study of ALKS 3831, a Novel Antipsychotic Therapy for the Treatment of SchizophreniaAlkermes plc (NASDAQ: ALKS) today announced positive topline results from a phase 1 study of its new antipsychotic candidate, ALKS 3831, a ... read more